Wolfram综合征2型单基因糖尿病中的可逆性线粒体铁毒性
患者成纤维细胞显示线粒体损伤、线粒体不稳定铁(mLI)升高25%(p<0.0001)和线粒体活性氧(mROS)升高28%(p<0.0001),DFP/NAC体外完全逆转上述异常;2例患者初步显示血糖控制和血小板聚集改善。
要点
- WS2表现为非典型青少年起病糖尿病,可伴精神疾病和先天性心脏缺陷。
- CISD2突变导致线粒体铁稳态紊乱和氧化应激,DFP/NAC可逆转细胞异常。
- DFP/NAC在2例患者中初步改善血糖控制和血小板聚集,需进一步临床试验。
核心结论
- WS2是由线粒体铁调控异常和氧化应激驱动的、易被低估的单基因糖尿病。
- 铁螯合剂DFP联合抗氧化剂NAC可逆转WS2细胞模型的线粒体铁毒性和氧化应激。
- DFP/NAC在2例患者中初步显示改善血糖控制和纠正血小板聚集,为未来临床试验提供机制依据。
研究设计与样本
- 观察性队列研究,结合离体功能细胞实验和概念验证性试点临床干预。
- 使用4例患者来源的成纤维细胞进行功能测定。
- 对成纤维细胞和2例患者给予铁螯合剂去铁酮(DFP)联合抗氧化剂N-乙酰半胱氨酸(NAC)治疗。
主要发现
- 患者为CISD2 c.109G>C奠基者突变纯合子,携带者率为1:40。
- 临床表型扩展至常见精神疾病和先天性心脏缺陷。
- 患者成纤维细胞显示严重线粒体和内质网损伤,线粒体不稳定铁(mLI)升高25%(p<0.0001),线粒体活性氧(mROS)升高28%(p<0.0001)。
- 体外DFP/NAC治疗完全逆转上述细胞异常。
- 在初步试点研究中,2例接受DFP/NAC治疗的患者报告血糖控制改善且血小板聚集得到纠正。
关键数值与推荐
- 患者为CISD2 c.109G>C突变纯合子,携带者率为1:40。
- 患者成纤维细胞mLI升高25%(p<0.0001),mROS升高28%(p<0.0001)。
- DFP/NAC体外治疗完全逆转mLI和mROS异常。
- 2例患者接受DFP/NAC后报告血糖控制改善,血小板聚集纠正。
临床怎么用
- 对非典型青少年起病糖尿病伴消化道出血、精神疾病或先天性心脏缺陷者,应警惕WS2并考虑CISD2基因检测。
- DFP/NAC联合治疗作为机制靶向干预,目前仅限研究背景,需临床试验验证后方可常规应用。
局限性
- 临床干预仅为2例患者的初步试点研究,样本量小。
- 细胞功能测定仅基于4例患者来源的成纤维细胞。
- 缺乏对照干预组和长期随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Wolfram syndrome type 2 (WS2) is a rare monogenic diabetes syndrome caused by CISD2 mutations. Its cellular pathophysiology remains poorly understood, and no targeted therapies exist. OBJECTIVE: To characterize the clinical phenotype and cellular pathophysiology of the largest WS2 cohort to date, and to evaluate a novel, mechanistically targeted pharmacological intervention. DESIGN: Observational cohort study paired with ex vivo functional cellular assays and a proof-of-concept pilot clinical intervention. SETTING: Multicenter academic and clinical institutions in Israel and the Palestinian territories. PATIENTS: Twenty-two patients from 11 unrelated Palestinian families presenting with atypical juvenile-onset diabetes and gastrointestinal bleeding. Patient-derived fibroblasts (n = 4) were utilized for functional assays. INTERVENTION(S): Fibroblasts and two patients were treated with a combination of the iron chelator deferiprone (DFP) and the antioxidant N-acetylcysteine (NAC). MAIN OUTCOME MEASURE(S): Clinical phenotype, CISD2 genetic analysis, mitochondrial labile iron (mLI) and reactive oxygen species (ROS) levels, organelle morphology, and preliminary clinical response (HbA1c, platelet aggregation). RESULTS: Patients were homozygous for a CISD2 c.109G > C founder mutation (carrier rate 1:40). The clinical phenotype was expanded to include prevalent psychiatric morbidity and congenital heart defects. Patient fibroblasts exhibited profound mitochondrial and endoplasmic reticulum damage, with increased mLI (+25%, p < 0.0001) and mROS (+28%, p < 0.0001). In vitro DFP/NAC treatment fully reversed these cellular anomalies. In a preliminary pilot study, two patients receiving DFP/NAC demonstrated improved reported glycemic control and corrected platelet aggregation. CONCLUSIONS: WS2 is an underdiagnosed monogenic diabetes driven by mitochondrial iron dysregulation and oxidative stress. Repurposing DFP/NAC reverses this toxicity, offering a strong mechanistic rationale for future clinical trials.
引用
- Cohen A, Karmi O, Abdulhag UN, et al. Reversible Mitochondrial Iron Toxicity in Wolfram Syndrome Type 2 Monogenic Diabetes. J Clin Endocrinol Metab. 2026. PMID: 42339507. doi:10.1210/clinem/dgag250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。